A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

• Register: ClinicalTrials.gov
• Last refreshed on: 8 January 2024
• Main ID: NCT04615273
• Date of registration: 29/10/2020
• Prospective Registration: Yes
• Primary sponsor: Ascendis Pharma Endocrinology Division A/S
• Public title: A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency foresiGHt
• Scientific title: foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
• Date of first enrolment: December 3, 2020
• Target sample size: 264
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/ct2/show/NCT04615273
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
• Phase: Phase 3

Countries of recruitment

Armenia, Australia, Canada, Denmark, France, Georgia, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, New Zealand, Poland, Romania, Serbia, Slovakia, Spain, Turkey, Ukraine, United Kingdom, United States

Key inclusion & exclusion criteria

Inclusion Criteria

1. Age between 23 and 80 years, inclusive, at screening.

2. AGHD Diagnosis Criteria

For adult-onset AGHD: documented history of structural hypothalamic-pituitary disease,
hypothalamic-pituitary surgery, cranial irradiation, 1-4 non-GH pituitary hormone
deficiencies, a proven genetic cause of GHD, or traumatic brain injury (TBI).

A. For all countries except Japan: Subjects must satisfy at least one of the following
criteria:

1. Insulin tolerance test: peak GH =5 ng/mL

2. Glucagon stimulation test according to body mass index (BMI)

- i. BMI =30 kg/m2: peak GH =3 ng/mL

- ii. BMI >30 kg/m2: peak GH =1 ng/mL

3. Three or four pituitary axis deficiencies (i.e., adrenal, thyroid, gonadal,
and/or vasopressin; not including GH) with IGF-1 SDS = -2.0 at screening

4. Macimorelin test: peak GH =2.8 ng/mL

5. Growth hormone releasing hormone (GHRH) + arginine test according to BMI:

- i. BMI <25 kg/m2, peak GH <11 ng/mL

- ii. BMI =25-=30 kg/m2, peak GH <8 ng/mL

- iii. BMI >30 kg/m2, peak GH <4 ng/mL

B. For Japan only: Subjects with AGHD and deficiency of at least one non-GH pituitary
hormones need to satisfy one of the following GH stimulation tests. Subjects with GHD
and evidence of intracranial structure disorder need to satisfy at least 2 of the
following stimulation tests:

1. Insulin tolerance test: peak GH =1.8 ng/mL

2. Glucagon test: peak GH =1.8 ng/mL

3. Growth Hormone Releasing Peptide-2 (GHRP-2) tolerance test: peak GH =9 ng/mL

3. IGF-1 SDS = -1.0 at screening as measured by central laboratory.

4. hGH treatment naïve or no exposure to hGH therapy or GH secretagogue for at least 12
months prior to screening.

5. For subjects on hormone replacement therapies for any hormone deficiencies other than
GH (e.g., adrenal, thyroid, estrogen, testosterone) must be on adequate and stable
doses for =6 weeks prior to and throughout screening.

6. For subjects not on glucocorticoid replacement therapy, documentation of adequate
adrenal function at screening defined.

7. For males not on testosterone replacement therapy: morning (6:00 - 10:00AM) total
testosterone within normal limits for age.

8. On a stable diet and exercise regime at screening with no intention to modify diet or
exercise pattern during the trial, i.e., no weight reduction program intended during
the trial or within the last 90 days prior to or through screening.

9. No plans to undergo bariatric surgery during the trial.

10. Fundoscopy at screening without signs/symptoms of intracranial hypertension or
diabetic retinopathy above stage 2 / moderate or above or any other retinal disease
contraindicated to growth hormone therapy. For subjects with a diagnosis of diabetes
mellitus at screening, this must be documented with a fundus photograph.

11. Able and willing to provide a written informed consent and authorization for protected
health information (PHI) disclosure in accordance with Good Clinical Practice (GCP).

12. Serum fT4 in the normal range at screening as measured by central laboratory.

Exclusion Criteria

1. Known Prader-Willi Syndrome and/or other genetic diseases that may have an impact on
an endpoint.

2. Diabetes mellitus at screening if any of the following criteria are met:

1. Poorly controlled diabetes, defined as HbA1c >7.5% at screening.

2. Diabetes mellitus (defined as HbA1c =6.5% and/or fasting plasma glucose =126
mg/dL and/or plasma glucose =200 mg/dL two hours after oral glucose tolerance
test) diagnosed <26 weeks prior to screening

3. Change in diabetes regimen (includes dose adjustment) within <90 days prior and
throughout screening

4. Use of any diabetes drugs other than metformin and/or DPP-4 inhibitors for a
cumulative duration of greater than 4 weeks within 12 months prior to screening

5. Diabetes-related complications at screening (i.e., nephropathy as judged by the
investigator, neuropathy requiring pharmacological treatment, retinopathy stage 2
/ moderate and above within 90 days prior to screening or during screening)

3. Active malignant disease or history of malignancy. Exceptions to this exclusion
criterion:

1. Resection of in situ carcinoma of the cervix uteri

2. Complete eradication of squamous cell or basal cell carcinoma of the skin

3. Subjects with GHD attributed to treatment of intracranial malignant tumors or
leukemia, provided that a recurrence-free survival period of at least 5 years
prior to screening is documented in the subject's file (based on a Magnetic
Resonance Imaging (MRI) result for intracranial malignant tumors)

4. Evidence of growth of pituitary adenoma or other benign intracranial tumor within the
last 12 months before screening.

5. Subjects with acromegaly without remission / with documented remission less than 24
months prior to screening.

6. Subjects with Cushing's disease without remission / with documented remission less
than 24 months prior to screening.

7. Subjects with prior cranial irradiation or hypothalamic-pituitary surgery: the
procedure took place less than 12 months prior to screening.

8. eGFR <60 mL/min/1.73m2 determined based on Modification of Diet in Renal Disease
(MDRD) equation.

9. Hepatic transaminases (i.e., AST or ALT) >3 times the upper limit of normal.

10. Heart failure NYHA class 3 or greater (NYHA 1994).

11. QTcF = 451 milliseconds on 12-lead ECG at screening.

12. Poorly controlled hypertension, defined as supine systolic blood pressure >159 mmHg
and/or supine diastolic blood pressure >95 mmHg at screening.

13. Cerebrovascular accident within 5 years prior to screening.

14. Anabolic steroids (other than gonadal steroid replacement therapy) or
oral/intravenous/intramuscular corticosteroids within 90 days prior to or throughout
screening.

15. Currently using or have used within 26 weeks prior to screening any weight-loss or
appetite-suppressive medications including orlistat, zonisamide, lorcaserin,
bupropion, topiramate, sibutramine, stimulants, GLP-1 receptor agonists, SGLT-2
inhibitors or medications that affects IGF-1 or GH measurements including cabergoline
at doses above 0.5 mg weekly or bromocriptine at doses above 20 mg weekly.

16. Known hi


Age minimum: 23 Years
Age maximum: 80 Years
Gender: All

Health Condition(s) or Problem(s) studied

Growth Hormone Deficiency

Endocrine System Diseases

Hormone Deficiency

Intervention(s)

Other: Placebo

Drug: Lonapegsomatropin

Drug: Somatropin

Primary Outcome(s)

Change from Baseline in Trunk Percent Fat [Time Frame: 38 weeks]

Secondary Outcome(s)

Change from Baseline in Total Body Lean Mass [Time Frame: 38 weeks]

Change from Baseline in Trunk Fat Mass [Time Frame: 38 weeks]

Evaluate serum IGF-1 and IGFBP-3 and IGF-1 SDS and IGFBP-3 SDS [Time Frame: 38 weeks]

Incidence of Treatment-Emergent Adverse Events [Time Frame: 38 weeks]

Evaluate serum hGH, lonapegsomatropin, and mPEG levels [Time Frame: 38 weeks]

Secondary ID(s)

2020-000929-42

TCH-306

Source(s) of Monetary Support

Please refer to primary and secondary sponsors